Priser
Platform
Blog
Om os
Download
1707
Grape King Bio
Taiwan Stock Exchange
0

Om

Grape King Bio Ltd. is a notable player in the biotechnology and health food industry, primarily engaged in the production of probiotics, health supplements, and various functional foods. Its primary function is to innovate and manufacture products that enhance well-being by utilizing cutting-edge biotechnological advancements. The company's offerings are diversified across consumer health supplements, sports nutrition products, and specialty ingredients catering to diverse health needs and dietary preferences. Grape King Bio Ltd. serves a broad range of sectors, including food and beverage, pharmaceuticals, and health-focused retail industries, making its impact felt across multiple facets of consumer and health goods markets. With a strong presence in Taiwan and expanding reach in international markets, Grape King Bio Ltd. holds a significant role in driving forward advancements within the nutraceutical space, responding to the growing global demand for natural and effective health solutions.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I GRAPE KING BIO MED ENDAVU: Køb Grape King Bio ($1707) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Grape King Bio, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

Ticker1707
Land
Taiwan
Hjemmesidegrapeking.com.tw
SektorSundhed
IndustriLægemiddelproducenter - Specialitet og generisk

Udbytter

6,4TWD
'21
6,1TWD
'22
6,9TWD
'23
6,9TWD
'24
6,9TWD
'25
2,2TWD
'26
Ex-udbytte-dato8. jan. 2026
Udbytteafkast1,95%

Analytikerskøn

Baseret på 1 analytiker

Stærkt købKøbHoldSælgStærkt sælg
0%100%0%0%0%